Overview

• Merck revised its 2025 revenue forecast to €20.9–22.4 billion, down from its earlier projection of €21.5–22.9 billion, citing US tariff policies and currency fluctuations.
• The company also lowered its operating profit outlook to €5.8–6.4 billion, reflecting uncertainties in its North American lab equipment business.
• Q1 2025 results showed a 3% revenue increase to €5.28 billion, with adjusted EBITDA rising 6% to €1.54 billion and net profit reaching €738 million.
• Merck confirmed the acquisition of US-based SpringWorks Therapeutics, aiming to strengthen its position in the US cancer treatment market despite geopolitical challenges.
• CEO Belén Garijo expressed confidence in Merck's ability to achieve sustainable growth in 2025 and beyond, supported by strong performance in pharmaceutical manufacturing and semiconductor materials.